Worldwide, breast carcinoma is the commonest cancer of women, with approximately 1.67 million new cases diagnosed in the year 2012, making up for 25% of all female cancers. Among the most common causes of cancer-related mortality worldwide, it ranks fifth, but is the most common cause of cancer related mortality in less developed countries.
INTRODUCTION
Worldwide, breast carcinoma is the commonest cancer of women, with approximately 1.67 million new cases diagnosed in the year 2012, making up for 25% of all female cancers. Among the most common causes of cancer-related mortality worldwide, it ranks fifth, but is the most common cause of cancer related mortality in less developed countries. 1 With current treatment regimens, almost 90% of breast cancer patients may survive up to 5 years. This survival is found strongly associated with the stage of disease at the time of diagnosis. 2 The management of breast cancer can be broadly divided into three categories-early breast cancer, locally advanced breast cancer and metastatic breast cancer. According to NCCN guidelines patients with early breast cancer with TNM staging T0, N1, M0 and TI-3, N0-1, M0 should be managed according to the clinical node negative or positive disease status. Clinical node negative is defined as non-palpable nodes and mammographically negative nodes in the axilla. Any patient with clinical node positive disease should be evaluated with a fine needle aspiration cytology (FNAC) or core needle biopsy of the node. FNAC or core biopsy negative nodes are considered clinically node negative. All patients with above TNM stage and clinical node negative axilla should undergo an axillary staging with sentinel lymph node biopsy (SLNB). 3 In early stage breast cancer the status of the axillary lymph nodes is a strong prognostic factor and SLNB is now the standard staging procedure to assess metastasis to the axillary lymph nodes. 4 In contrast, axillary lymph node dissection (ALND) was conventionally, a regular element in surgical management of even early breast cancer. The advantages of ALND included-benefit on disease control like recurrence in axilla and thus survival, as a prognostic procedure, and it thus helped in adjuvant treatment selection. On the down side, the lymphatic disruption caused by ALND may give rise to lymphedema, shoulder dysfunction and chronic pain due to varying degrees of nerve injury, these eventually affect the functional outcome, as well as the patient's quality of life negatively. An intra-operative evaluation of SLNB with good accuracy can help the surgeon with decision for level of axillary dissection (AD) and spare the morbidity of complete level III ALND or second surgical procedure. 5 Although a histopathology of lymph nodes using a standard hematoxylin and eosin staining (HPE) is recommended by the American Society of Clinical Oncology guidelines, surgeons frequently request intraoperative assessment of SLNB using frozen section (FS) technique. 6, 7 There are some potential problems with the FS method-loss of fatty nodal tissue, interpretation of artifact impacting and lack of standardized method for FS evaluation of SLNB. This may result in extensive interobserver variability due to the quantity of nodal tissue examined and also due to the number of sections examined for every specimen. 8 This prospective study was designed to study the sensitivity and specificity of FS of SLNB with HPE as gold standard.
METHODS
This prospective observational study was performed at Cancer Research Institute, Swami Rama Himalayan University, Dehradun, India between July 2017 and November 2018, after an institutional ethics clearance. All carcinoma breast patients with TNM stage TI-3, N0, M0 with clinically node negative axilla were evaluated for enrolment in the study, after a written informed consent. Clinical node negative axilla was defined as -no palpable nodes and mammographically negative nodes.
Exclusion criteria
 FNAC or core biopsy proven axillary node metastasis in clinically N1 axilla.  Previous ipsilateral axillary surgery.
The demographic and disease related data was collected for the patients. At the time of definitive surgery for the primary tumor all patients underwent SLNB. The SLNB tissue was submitted for intra-operative FS. A gross evaluation was performed first to establish the number of nodes and grossly suspicious nodes. All nodes were measured for size, nodes up to 4 mm were frozen whole, rest were bisected into half-one for FS and one preserved for HPE. For FS, the nodes were sectioned to 4 mm width and examined. Definition of nodal macrometastasis wastumor nest more than 2 mm in diameter; micrometastasis was-tumor nest greater than 0.2 mm and less than or equal to 2 mm. Presence of extra-nodal involvement by tumor was also noted if metastases were detected. Data was collected for presence of nodal metastasis on FS and HPE of SLNB for each patient.
Statistical analysis
The data was entered in MS Excel 2010 and statistical analysis was performed with SPSS software version 22. One-sample, Kolmogorov-Smirnov test decided the normality of the data sets. The Parametric tests were used to analyse normally distributed data and Non-parametric tests for non-normally distributed data. The categorical data was analysed with Chi square test. A two by two table (Table 1) of results of FS and HPE (gold standard) was prepared and the following formulae were used for calculation. was not performed due to logistic reasons. These patients were excluded from the study.
(SLNB-sentinel lymph node biopsy, SLN-sentinel lymph node, FS-frozen section). In 55 patients an intra-operative FS evaluation of the SLN was performed. All patients were female; the mean age was 53 years (range 30-84±15.09 SD). The age distribution, the side of tumor and quadrant distribution is shown in Table 2 . The primary tumor was clinically staged as either T1 (23.6%) or T2 (76.4%); all patients had clinically N0 axilla and no evidence of distant metastasis. On histopathology 20%, 76.4% and 3.6% patients had T1, T2 and T3 primary tumors respectively ( Figure 2) ; 10.9%, 81.8% and 7.3% tumors were grade I, II and III respectively ( Figure 3) ; 34.5% tumors demonstrated lymphovascular invasion and 25.5% perineural invasion ( Figure 4 ). 7% (4) grade-I grade-II grade-III (FS-frozen section, HPE-histopathology, SLNB-sentinel lymph node biopsy, SLN-sentinel lymph node, PPV-positive predictive value, NNV-negative predictive value, CI-confidence interval). (SLN-sentinel lymph node, SLNB-sentinel lymph node biopsy, FS-frozen section, HPE-histopathology).
A median of four SLN were identified with a mean size of 13.84 mm ( (Table 5) .
DISCUSSION
In patients with early breast cancer SLNB is a precise technique for screening the axillary lymph nodes. Moreover, a negative SLNB for metastasis can prevent the morbidity of a complete ALND. [9] [10] [11] Nevertheless, current studies have questioned the need for intraoperative assessment of SLNB, especially in situations when complete ALND may not be done even in the presence of metastasis in SLN. The ACOSOG Z0011 study performed in patients with early breast cancer demonstrated no difference in loco-regional disease recurrence in patients with 1-2 SLN metastasis, who were randomized to either SLNB only or SLNB and ALND; with no inferior survival with the use of SLNB alone compared with ALND in a selective patient population (i.e. patients with clinically negative axilla, tumor size less than 20 mm, and 1 or 2 positive nodes). 12, 13 In our study only 6 (10.9%) patients had 3 or more SLN metastasis on HPE; thus, applying Z0011 criteria 89.1% patients could potentially avoid an ALND if they all had undergone a breast conserving surgery and received postoperative radiotherapy. Overall, in patients with negative SLN on FS (41/55)-46.34% underwent SLNB alone, 9.76% patients underwent a complete ALND and rest a level II ALND (following the study criteria of intraoperative clinically suspicious enlarged nodes); in patients with negative SLN on HPE (39/55)-48.72% underwent SLNB alone, 10.25% patients underwent a complete ALND and rest a level II ALND in our study ( Table 4) . Some have even further questioned the need of any SLNB evaluation at all, suggesting that the preoperative axillary ultrasound evaluation of nodes and fine needle aspiration cytology (FNAC) of suspicious nodes could be enough to guide the decision regarding ALND. 14, 15 Other concerns for the doubt regarding need for intraoperative assessment of SLNB are the different methods used (FS vs. touch prep imprint cytology) and the quantity of tissue utilised for intra-operative assessment. A review of literature reveals various techniques for intra-operative assessment of the SLNB. 16 Guidelines published by the College of American Pathologists for the processing of SLNB focus on grossing and processing aspect of the specimen for HPE only, but there is no guideline on preferred technique for intra-operative assessment-either FS or touch prep. 17, 18 In a study published in 2012, 126 early breast cancer women with T1 tumors were prospectively enrolled, 221 axillary nodes were assessed intra-operatively with FS and imprint cytology (IC). The sensitivity, specificity and accuracy of FS was found to be 75.7%, 100% and 91.9%; of IC was found to be 70.3%, 98.6% and 89.1%. (SLN-sentinel lymph node, FS-frozen section, HPE-histopathology, IHC-immunohistochemistry).
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Another study from Switzerland assessed 279 axillary nodes from 149 carcinoma breast patients with the intent of assessing the diagnostic accuracy of intra-operative FS evaluation of SLNB for micrometastasis. They found the sensitivity of FS for macrometastasis to be 83.3% and for micrometastasis to be only 40%. The specificity was 100%. On literature search the sensitivity of intraoperative FS of SLNB varied from 68% to 98% for macrometastasis (Table 6 ), in the current study the sensitivity of 81.25% was well within this range. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The large variation in accuracy of intra-operative assessment of SLNB reflects the different techniques being employed for FS analysis. These differences in techniques include-the intervals used for cutting of lymph nodes, number of cut sections analysed and if immunohistochemistry (IHC) was used with HPE as gold standard for comparison, as well as use of perioperative IHC. 27 The NCCN guidelines do not recommend ALND for only micrometastasis or isolated tumor cells on IHC. 3 Thus, we do not see the need for diagnosing these during an intra-operative assessment of SLNB.
With the FS protocol used at our institute of bisecting all sentinel lymph nodes for FS, with 4mm sectioning of bisected nodal tissue for FS and HPE for rest of the bisected nodal tissue, the sensitivity and accuracy in our study was 81.25% and 92.73% respectively. An intraoperative assessment of SLNB can potentially guide the surgical team towards the level of axillary dissection, save the morbidity of complete ALND and a second axillary surgery. 
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